Corporate Support
Sitemap

Features

Customer Services

Events

Terms of Use

Singapore
Malaysia

ShareInvestor.com

Mobile Edition
Mode - Streaming
Switch to Static Mode?

Price Highlight

Index Highlight

Chart
STI
2,975.1
50.5 (1.73%)

 

  • STI Straits Times Index
    2,975.1
    50.5 (1.73%)
     
  • KLCI FTSE Bursa Malaysia KLCI
    1,584.0
    26.4 (1.70%)
    Index delayed 15 minutes
  • HSI Hang Seng Index
    30,074.2
    355.9 (1.20%)
    Index delayed 15 minutes
  • SSE SSE Composite Index
    3,585.0
    21.0 (0.59%)
    Index delayed 15 minutes
  • N225 Nikkei 225
    29,671.7
    -
    Index delayed 20 minutes
  • JCI Jakarta Composite Index
    6,289.6
    38.6 (0.62%)
    Index delayed 10 minutes

SGX Market

Bursa Market

HKEx Market

SET Market

IDX Market

ASX Market

NYSE Market

NASDAQ Market

NYSE American Market

  • Volume: 1,531.1M
  • Value: 1,587.9M
  • Rise: 238
  • Fall: 113
  • Unch: 425

Intraday Market Ticker Help

Intraday Market Ticker
Time Name Type Price Vol

  • Top Active

  • Top Gainer

  • Top Loser

Top Counters
Name Last Change
Thomson Medical0.116+0.007
Shen Yao0.004-
Oceanus^0.074+0.003
Secura0.099+0.013
Jiutian Chemical0.096-
Sembcorp Marine0.156+0.004
ThaiBev0.735+0.015
YZJ Shipbldg SGD1.060+0.020
ComfortDelGro1.620+0.030
SIA4.990+0.300

World Indices

World Indices
Name Last Change
Nasdaq 13,598.0 +132.8
HSI 30,074.2 +355.9
HSCEI 11,717.4 +207.7
Jakarta 6,289.6 +38.6
Nikkei 225 29,671.7
SSE Comp 3,585.0 +21.0
Shanghai A 3,758.0 +22.0
Shanghai B 245.9
KOSPI 3,099.7 +104.7

Asian Indices delayed. US Indices updated twice daily at 7:30am and 7:30pm.

Fundamental - Factsheet

Help

  • Factsheet

  • Print

ALPHAMAB-B ALPHAMAB-B
Quotes 15 Minutes Delayed. Updated at 25 Feb 2021 16:08
Last (HKD): 13.320 Change: +1.020 High: 13.320 Remarks: -
Change (%): +8.29 Low: 12.500
Open 12.500 Yesterday's Close 12.300
Buy Price 13.260 Sell Price 13.320
Buy Volume ('000) 1 Sell Volume ('000) 28
Cumulative Volume ('000) 2,461 Cumulative Value 31,934,180
 
Click to show Stock Prices chart

Key Statistics

EPS (HKD) a -1.00997 Trailing EPS (HKD) e -1.00997 NAV (HKD) b 3.0286
PE a - Trailing PE f - Price / NAV b 4.3981
Dividend (HKD) d - Cash In Hand (HKD) g 0.2815 Issued & Paid-up Shares c 934,939,000
Dividend Yield (%) d - Price / Cash In Hand g 47.318 Treasury Shares h -
Beta - 75 Daysi 0.655 R-Squared - 75 Days(%)i 7.56 Market Cap (M) 12,453.387
Beta - 500 Daysi 0.936 R-Squared - 500 Days (%)i 10.38 Enterprise Value (M) 10,012.328
Piotroski F Score 3 Exchange Code 9966 Par Value ( USD ) n.a.
52 Weeks Volatility (%) 52.63 6-Month VWAP 15.507 Free Float (%) 45.1
Sector & Industry Health Technology - Biotechnology
Notes:
  1. Based on latest Full Year results announcement, adjusted for the current number of shares.
  2. Based on latest results announcement (Full Year, Half Year or Interim), adjusted for carrying value of "Other Share Capital", illustrative financial effects of corporate actions (if applicable) and the current number of shares.
  3. Rounded to the nearest thousand. Updated on 18 Nov 2020.Please click here for more information.
  4. Dividend is based on latest Full Year results announcement, adjusted for current number of shares and excludes special dividend.
  5. Summation of the earnings from the latest 4 Quarter (or 2 Half Year) results announcement, adjusted for the current number of shares.
  6. Based on Trailing EPS.
  7. Based on reported cash and cash equivalents at end and extracted from the latest results announcement (Full Year, Half Year or Interim), adjusted for the current number of shares.
  8. Rounded to the nearest thousand. Updated on 05 Dec 2019.
  9. Beta and R-Squared are calculated in relation to the market index using the historical daily closing values of the stock and index as data points.

Peer Comparison

Type Name Market Market Cap (M)a PE b Trailing PE c Price / NAV d Dividend Yield (%)d
Reference ALPHAMAB-B HKEx 12,453.387 - - 4.3981 -
Industry Biotechnology HKEx 51,014.289 - - 8.5901 0.112
Local Peer WUXI BIO HKEx 439,118.645 381.981 304.963 29.3960 -
Local Peer BEIGENE HKEx 236,406.996 - - 7.1147 -
Local Peer SINO BIOPHARM HKEx 164,621.039 53.635 64.329 4.5675 0.609
Local Peer ZAI LAB-SB HKEx 104,836.822 - - 29.0602 -
Local Peer GENSCRIPT BIO HKEx 28,616.048 - - 3.9138 -
Local Peer 3SBIO HKEx 20,882.956 18.914 13.908 1.7852 -
Local Peer JW THERAP-B HKEx 17,146.786 - - -16.9188 -
Local Peer JACOBIO-B HKEx 16,200.702 - - -11.5233 -
Local Peer VIVA BIOTECH HKEx 13,069.302 43.351 - 6.2822 0.239
Local Peer HAOHAI BIOTEC HKEx 11,565.197 27.508 48.359 1.8999 1.178
Local Peer FRONTAGE HKEx 10,873.977 75.298 102.906 5.1553 -
Local Peer JHBP-B HKEx 9,800.959 - - 64.1388 -
Other Local Peers ASCENTAGE-B (HKEx), KINTOR PHARMA-B (HKEx), SINOMAB BIO-B (HKEx), ASCLETIS-B (HKEx), LEE'S PHARM (HKEx), ESSEX BIO-TECH (HKEx), UNI-BIO GROUP (HKEx), REGENT PACIFIC (HKEx), CT ENTERPRISE (HKEx)
Global Peer AMGEN INC NASDAQ 132,834.404 18.287 18.287 14.1178 2.786
Global Peer CSL LTD ASX 121,921.264 38.874 32.036 11.5375 1.095
Global Peer GILEAD SCIENCES INC NASDAQ 79,892.340 649.506 649.531 4.3846 4.269
Global Peer ILLUMINA INC NASDAQ 67,267.195 102.541 102.541 14.3305 -
Global Peer MODERNA INC NASDAQ 57,294.851 - - 20.7605 -
Global Peer VERTEX PHARMACEUTICAL NASDAQ 56,421.718 20.807 20.807 6.4951 -
Global Peer REGENERON PHARMACEUTICALS INC NASDAQ 49,130.721 13.985 13.985 4.4562 -
Global Peer BIOGEN INC NASDAQ 43,071.481 10.766 10.766 4.0253 -
Global Peer ALEXION PHARMACEUTICAL INC NASDAQ 33,964.318 56.288 56.288 2.9151 -
Global Peer BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS NASDAQ 30,634.978 - - 7.1452 -
Other Global Peers SEAGEN INC (NASDAQ), BIONTECH SE SPON ADS EACH REP 1 ORD SHS (NASDAQ), EXACT SCIENCES CORP (NASDAQ), 10X GENOMICS INC (NASDAQ), ALNYLAM PHARMACEUTICALS INC (NASDAQ), INCYTE CORPORATION (NASDAQ), NOVAVAX INC (NASDAQ), BIOMARIN PHARMACEUTICAL (NASDAQ), BIO-TECHNE CORP (NASDAQ), ZAI LAB LIMITED ADS EACH REP 1 ORD SHS (NASDAQ), ABCELLERA BIOLOGICS INC (NASDAQ), CRISPR THERAPEUTICS AG (NASDAQ), NEUROCRINE BIOSCIENCES INC (NASDAQ), MIRATI THERAPEUTICS INC (NASDAQ), BRIDGEBIO PHARMA INC (NASDAQ), ULTRAGENYX PHARMACEUTICAL INC (NASDAQ), FATE THERAPEUTICS (NASDAQ), ARROWHEAD PHARMACEUTICALS INC (NASDAQ), ACCELERON PHARMA (NASDAQ), VIR BIOTECHNOLOGY INC (NASDAQ), ACADIA PHARMACEUTICALS INC (NASDAQ), IONIS PHARMACEUTICALS INC (NASDAQ), DENALI THERAPEUTICS INC (NASDAQ), PACIFIC BIOSCIENCES CALIFORNIA INC (NASDAQ), EXELIXIS INC (NASDAQ), SAREPTA THERAPEUTICS INC (NASDAQ), TWIST BIOSCIENCE CORPORATION (NASDAQ), HALOZYME THERAPEUTICS INC (NASDAQ), KODIAK SCIENCES INC (NASDAQ), TG THERAPEUTICS INC (NASDAQ), SANA BIOTECHNOLOGY INC (NASDAQ), IOVANCE BIOTHERAPEUTICS INC (NASDAQ), BLUEPRINT MEDICINES CORP (NASDAQ), GALAPAGOS NV SPON ADR REPR 1 ORD SHS (NASDAQ), BEAM THERAPEUTICS INC (NASDAQ), ABCAM PLC SPON ADS EACH REP 1 ORD SHS (NASDAQ), EMERGENT BIOSOLUTIONS INC (NYSE), ALLOGENE THERAPEUTICS INC (NASDAQ), FIBROGEN INC (NASDAQ), CHINA BIOLOGIC PRODUCTS HLDGS INC (NASDAQ), CHEMOCENTRYX INC (NASDAQ), Lonza (SGX), ARENA PHARMACEUTICALS INC (NASDAQ), VERACYTE INC (NASDAQ), INSMED INC (NASDAQ), PTC THERAPEUTICS INC (NASDAQ), AGIOS PHARMACEUTICALS INC (NASDAQ), INTELLIA THERAPEUTICS INC (NASDAQ), RELAY THERAPEUTICS INC (NASDAQ), ARVINAS INC (NASDAQ), NANTKWEST INC (NASDAQ), MORPHOSYS SPON ADS EACH REP 0.25 ORD SHS (NASDAQ), NANOSTRING TECHNOLOGIES INC (NASDAQ), ROCKET PHARMACEUTICALS INC (NASDAQ), EDITAS MEDICINE INC (NASDAQ), SEER INC (NASDAQ), PRELUDE THERAPEUTICS INC (NASDAQ), ALKERMES PLC (NASDAQ), AMICUS THERAPEUTICS INC (NASDAQ), SORRENTO THERAPEUTICS INC (NASDAQ), GLOBAL BLOOD THERAPEUTICS INC (NASDAQ), INTRA-CELLUAR THERAPIES INC (NASDAQ), VIELA BIO INC (NASDAQ), BIONANO GENOMICS INC (NASDAQ), XENCOR INC (NASDAQ), ALLOVIR INC (NASDAQ), DECIPHERA PHARMACEUTICALS INC (NASDAQ), LIGAND PHARMACEUTICAL INC (NASDAQ), KYMERA THERAPEUTICS INC (NASDAQ), NUVATION BIO INC (NYSE), MYRIAD GENETICS INC (NASDAQ), STOKE THERAPEUTICS INC (NASDAQ), ARCUS BIOSCIENCES INC (NYSE), KURA ONCOLOGY INC (NASDAQ), NGM BIOPHARMACEUTICALS INC (NASDAQ), APPLIED MOLECULAR TRANSPORT INC (NASDAQ), MYOVANT SCIENCES LTD (NYSE), DICERNA PHARMACEUTICALS INC. (NASDAQ), IMMUNOCORE HLDGS PLC SPON ADS EACH REP ONE ORD SHS (NASDAQ), BIOCRYST PHARMACEUTICALS INC (NASDAQ), SERES THERAPEUTICS (NASDAQ), COMPASS PATHWAYS PLC UNSPON ADS REP 1 ORD SHS (NASDAQ), AURINIA PHARMACEUTICALS INC (NASDAQ), C4 THERAPEUTICS INC (NASDAQ), NKARTA INC (NASDAQ), SANGAMO THERAPEUTICS INC (NASDAQ), BLUEBIRD BIO INC (NASDAQ), IMMUNOGEN INC (NASDAQ), TRAVERE THERAPEUTICS INC (NASDAQ), TRANSLATE BIO INC (NASDAQ), PRECIGEN INC (NASDAQ), BIOATLA INC (NASDAQ), REPLIMUNE GROUP INC (NASDAQ), REGENXBIO INC (NASDAQ), SCHOLAR ROCK HOLDING CORPORATION (NASDAQ), PURETECH HEALTH PLC SPON ADS EACH REP 10 ORD SHS (NASDAQ), IMMUNOVANT INC (NASDAQ), FREQUENCY THERAPEUTICS INC (NASDAQ), HERON THERAPEUTICS INC (NASDAQ), GRACELL BIOTECHNOLOGIES INC SPON ADS EACH REP 5 ORD SHS (NASDAQ), OCUGEN INC (NASDAQ), VOR BIOPHARMA INC (NASDAQ), UNIQURE N.V. (NASDAQ), SHATTUCK LABS INC (NASDAQ), ZENTALIS PHARMACEUTICALS INC (NASDAQ), PERSONALIS INC (NASDAQ), CYTOKINETICS INC (NASDAQ), ITEOS THERAPEUTICS INC (NASDAQ), ATARA BIOTHERAPEUTICS INC (NASDAQ), ALECTOR INC (NASDAQ), OMEROS CORP (NASDAQ), BIOXCEL THERAPEUTICS INC (NASDAQ), LUMINEX CORP(DEL) (NASDAQ), RHYTHM PHARMACEUTICALS INC (NASDAQ), MERSANA THERAPEUTICS INC (NASDAQ), ADVERUM BIOTECHNOLOGIES INC (NASDAQ), POLYNOVO LIMITED (ASX), TRILLIUM THERAPEUTICS INC (NASDAQ), VAXCYTE INC (NASDAQ), MANNKIND CORPORATION (NASDAQ), MESOBLAST LTD (ASX), PLIANT THERAPEUTICS INC (NASDAQ), MESOBLAST LTD SPON ADR EACH REP 5 SHS (NASDAQ), COHERUS BIOSCIENCES INC (NASDAQ), MACROGENICS INC (NASDAQ), FIVE PRIME THERAPEUTICS (NASDAQ), AVID BIOSERVICES INC (NASDAQ), PROTAGONIST THERAPEUTICS INC (NASDAQ), KARYOPHARM THERAPEUTICS INC (NASDAQ), 4D MOLECULAR THERAPEUTICS INC (NASDAQ), MORPHIC HOLDING INC (NASDAQ), EPIZYME INC (NASDAQ), MIMEDX GROUP INC (NASDAQ), LEXICON PHARMACEUTICALS INC (NASDAQ), ENANTA PHARMACEUTICALS INC (NASDAQ), SYNDAX PHARMACEUTICALS INC (NASDAQ), VANDA PHARMACE INC (NASDAQ), ZIOPHARM ONCOLOGY INC (NASDAQ), BLACK DIAMOND THERAPEUTICS INC (NASDAQ), TAYSHA GENE THERAPIES INC (NASDAQ), DYNAVAX TECHNOLOGIES CORP (NASDAQ), INHIBRX INC (NASDAQ), DYNE THERAPEUTICS INC (NASDAQ), AVIDITY BIOSCIENCES INC (NASDAQ), CARA THERAPEUTICS INC (NASDAQ), HUMANIGEN INC (NASDAQ), PASSAGE BIO INC (NASDAQ), CORTEXYME INC (NASDAQ), CELLECTIS ADS EACH REPR 1 ORD SPON (NASDAQ), RUBIUS THERAPEUTICS INC (NASDAQ), ADAPTIMMUNE THERAPEUTICS PLC SPON ADS EACH REP 6 ORD SHS (NASDAQ), MERIDIAN BIOSCIENCE INC COM (NASDAQ), SIGILON THERAPEUTICS INC (NASDAQ), TELIX PHARMACEUTIC (ASX), COMPUGEN (NASDAQ), RADIUS HEALTH INC (NASDAQ), PROTHENA CORP PLC (NASDAQ), ANAVEX LIFE SCIENCES CORPORATION (NASDAQ), CHIMERIX INC (NASDAQ), SOLID BIOSCIENCES INC (NASDAQ), CURIS INC (NASDAQ), VBI VACCINES INC CDA (NASDAQ), ATHIRA PHARMA INC (NASDAQ), MERUS B V (NASDAQ), AGENUS INC (NASDAQ), KADMON HLDGS INC (NASDAQ), ASPIRA WOMENS HEALTH INC (NASDAQ), ESPERION THERAPEUTICS INC (NASDAQ), VAXART INC (NASDAQ), PANDION THERAPEUTICS INC (NASDAQ), ANAPTYSBIO INC (NASDAQ), RIGEL PHARMACEUTICALS INC (NASDAQ), IMMATICS N V (NASDAQ), MEIRAGTX HOLDINGS PLC (NASDAQ), ACTINIUM PHARMACEUTICALS INC (NYSE American), ATRECA INC (NASDAQ), ALTIMMUNE INC (NASDAQ), MOLECULAR TEMPLATES INC (NASDAQ), POSEIDA THERAPETUICS INC (NASDAQ), ARDELYX INC (NASDAQ), AFFIMED N V (NASDAQ), AKOUOS INC (NASDAQ), SUMMIT THERAPEUTICS INC (NASDAQ), DBV TECHNOLOGIES SPON ADR EACH REPR 0.5 ORD (NASDAQ), AKEBIA THERAPEUTICS INC (NASDAQ), GERON CORP (NASDAQ), INVENTIVA SA SPON ADS EACH REP 1 ORD SHS (NASDAQ), HARPOON THERAPEUTICS INC (NASDAQ), FOGHORN THERAPEUTICS INC (NASDAQ), XENON PHARMACEUTICALS INC (NASDAQ), SYROS PHARMACEUTICALS INC (NASDAQ), PRECISION BIOSCIENCES INC (NASDAQ), FLEXION THERAPEUTICS INC (NASDAQ), DPHARMA (Bursa), XBIOTECH INC (NASDAQ), COGENT BIOSCIENCES INC (NASDAQ), IVERIC BIO INC (NASDAQ), SPECTRUM PHARMACEUTICALS INC (NASDAQ), CLOVIS ONCOLOGY INC (NASDAQ), FREELINE THERAPEUTICS HLDGS PLC SPON ADS EACH REP 1 ORD SHS (NASDAQ), AQUABOUNTY TECHNOLOGIES INC (NASDAQ), LANDOS BIOPHARMA INC (NASDAQ), ALDEYRA THERAPEUTICS (NASDAQ), HOMOLOGY MEDICINES INC (NASDAQ), BICYCLE THERAPEUTICS PLC SPON ADS EACH REP 1 ORD SHS (NASDAQ), NEOLEUKIN THERAPEUTICS INC (NASDAQ), VIKING THERAPEUTICS INC (NASDAQ), MAGENTA THERAPEUTICS INC (NASDAQ), SENSEI BIOTHERAPEUTICS INC (NASDAQ), SPRUCE BIOSCIENCES INC (NASDAQ), CYTOMX THERAPEUTICS INC (NASDAQ), UROGEN PHARMA LTD (NASDAQ), WAVE LIFE SCIENCES LTD (NASDAQ), ADICET BIO INC (NASDAQ), SQZ BIOTECHNOLOGIES CO (NYSE), BIOVIE INC (NASDAQ), RAPT THERAPEUTICS INC (NASDAQ), SINOVAC BIOTECH LTD (NASDAQ), AVROBIO INC (NASDAQ), OPTHEA LIMITED SPON ADS EACH REPR 8 ORD SHS (NASDAQ), TERNS PHARMACEUTICALS INC (NASDAQ), SELECTA BIOSCIENCES INC (NASDAQ), OPTHEA LIMITED (ASX), SESEN BIO INC (NASDAQ), DECIBEL THERAPEUTICS INC (NASDAQ), AUTOLUS THERAPEUTICS PLC SPON ADS EA REP 1 ORD SHS (NASDAQ), JOUNCE THERAPEUTICS INC (NASDAQ), PUMA BIOTECHNOLOGY INC (NASDAQ), ATHERSYS INC (NASDAQ), ONCORUS INC (NASDAQ), CO DIAGNOSTICS INC (NASDAQ), MEREO BIOPHARMA GROUP PLC SPON ADS EACH REP 5 ORD SHS (NASDAQ), CUE BIOPHARMA INC (NASDAQ), VERASTEM INC (NASDAQ), GREENWICH LIFESCIENCES INC (NASDAQ), XOMA CORP (NASDAQ), IMUGENE LIMITED (ASX), 22ND CENTURY GROUP INC (NYSE American), LINEAGE CELL THERAPEUTICS INC (NYSE American), CELLULAR BIOMEDICINE GROUP INC (NASDAQ), FORTE BIOSCIENCES INC (NASDAQ), UNITY BIOTECHNOLOGY INC (NASDAQ), OUTLOOK THERAPEUTICS INC (NASDAQ), SURFACE ONCOLOGY INC (NASDAQ), APTOSE BIOSCIENCES INC (NASDAQ), ANTEOTECH LIMITED (ASX), VISTAGEN THERAPEUTICS INC (NASDAQ), 9 METERS BIOPHARMA INC (NASDAQ), FORTRESS BIOTECH INC (NASDAQ), EIGER BIOPHARMACEUTICALS INC (NASDAQ), TREVENA INC (NASDAQ), PARATEK PHARMACEUTICALS INC (NASDAQ), ONCONOVA THERAPEUTICS INC (NASDAQ), AEGLEA BIOTHERAPEUTICS INC (NASDAQ), INNATE PHARMA SPON ADS EACH REP 1 ORD SHS (NASDAQ), CYMABAY THERAPEUTICS INC (NASDAQ), EVOFEM BIOSCIENCES INC (NASDAQ), ARBUTUS BIOPHARMA CORP (NASDAQ), T2 BIOSYSTEMS INC (NASDAQ), CASI PHARMACEUTICALS INC (NASDAQ), NEXTCURE INC (NASDAQ), CHECKMATE PHARMACEUTICALS INC (NASDAQ), TIZIANA LIFE SCIENCES PLC SPON ADS EACH REPR 10 ORD SHS (NASDAQ), BELLUS HEALTH INC (NASDAQ), IMMUNOME INC (NASDAQ), KAMADA LTD (NASDAQ), INFINITY PHARMACEUTICALS INC (NASDAQ), ITERUM THERAPEUTICS PLC (NASDAQ), NUCANA PLC SPON ADR EACH REP 1 ORD SHS (NASDAQ), MEDICINOVA INC (NASDAQ), NEPTUNE WELLNESS SOLUTIONS INC (NASDAQ), EDAP TMS S.A. SPON ADR EACH REPR 1 ORD SHARE (NASDAQ), CABALETTA BIO INC (NASDAQ), LARIMAR THERAPEUTICS INC (NASDAQ), ALPINE IMMUNE SCIENCES INC (NASDAQ), NANOVIRICIDES INC (NYSE American), IMMUNOPRECISE ANTIBODIES LTD (NASDAQ), KEZAR LIFE SCIENCES INC (NASDAQ), AVEO PHARMACEUTICALS INC (NASDAQ), VOYAGER THERAPEUTICS INC (NASDAQ), EVOGENE LTD (NASDAQ), EQUILLIUM INC (NASDAQ), IMV INC (NASDAQ), TAIWAN LIPOSOME COMPANY LTD SPON ADS EACH REP 2 ORD SHS (NASDAQ), ADMA BIOLOGICS INC (NASDAQ), APPLIED GENETIC TECHNOLOGIES CORP (NASDAQ), INMUNE BIO INC (NASDAQ), CHIASMA INC (NASDAQ), STRONGBRIDGE BIOPHARMA PLC (NASDAQ), METACRINE INC (NASDAQ), AXCELLA HEALTH INC (NASDAQ), PROQR THERAPEUTICS N V (NASDAQ), BIONOMICS LTD (ASX), MEDICENNA THERAPEUTICS CORP (NASDAQ), CORBUS PHARMACEUTICALS HOLDINGS IN (NASDAQ), SEELOS THERAPEUTICS INC (NASDAQ), NEXT SCIENCE LTD (ASX), CONCERT PHARMACEUTICALS INC (NASDAQ), CALITHERA BIOSCIENCES INC (NASDAQ), FENNEC PHARMACEUTICALS INC (NASDAQ), PLURISTEM THERAPEUTICS INC (NASDAQ), GENFIT SPON ADS EACH REP 1 ORD SHS (NASDAQ), IMMUTEP LTD (ASX), HEAT BIOLOGICS INC (NASDAQ), IBIO INC (NYSE American), ERYTECH PHARMA SPON ADR EACH REPR 1 ORD (NASDAQ), CATALYST BIOSCIENCES INC (NASDAQ), HARVARD BIOSCIENCE INC (NASDAQ), ENOCHIAN BIOSCIENCES INC (NASDAQ), DIAMEDICA THERAPEUTICS INC (NASDAQ), VTV THERAPEUTICS INC (NASDAQ), ONCOLYTICS BIOTECH INC (NASDAQ), SIO GENE THERAPIES INC (NASDAQ), ORGENESIS INC (NASDAQ), CEL-SCI CORP (NYSE American), BIOFRONTERA AG SPON ADS EACH REP TWO ORD SHS (NASDAQ), GLYCOMIMETICS INC (NASDAQ), GENOCEA BIOSCIENCES INC (NASDAQ), IDERA PHARMACEUTICALS INC (NASDAQ), LIMINAL BIOSCIENCES INC (NASDAQ), AZIYO BIOLOGICS INC (NASDAQ), DYADIC INTERNATIONAL INC (NASDAQ), LEAP THERAPEUTICS INC (NASDAQ), SIERRA ONCOLOGY INC (NASDAQ), CHAMPIONS ONCOLOGY INC (NASDAQ), CONTRAFECT CORP (NASDAQ), ELOXX PHARMACEUTICALS INC (NASDAQ), X4 PHARMACEUTICALS INC (NASDAQ), LA JOLLA PHARMACEUTICAL CO (NASDAQ), APTEVO THERAPEUTICS INC (NASDAQ), BRAINSTROM CELL THERAPEUTICS (NASDAQ), PIERIS PHARMACEUTICALS INC (NASDAQ), ENZO BIOCHEM INC (NYSE), KAZIA THERAPEUTICS LIMITED (ASX), MINERVA NEUROSCIENCES INC (NASDAQ), SYNLOGIC INC (NASDAQ), EVAXION BIOTECH AS SPON ADS EACH REP 1 ORD SHS (NASDAQ), OTONOMY INC (NASDAQ), INFLARX N V (NASDAQ), AETERNA ZENTARIS INC (NASDAQ), ARAVIVE INC (NASDAQ), IMMUTEP LTD SPON ADS EACH REP 10 ORD SHS (NASDAQ), TRACON PHARMACEUTICALS INC (NASDAQ), GALECTIN THERAPEUTICS INC (NASDAQ), ASLAN PHARMACEUTICALS LIMITED ADS EACH REP 5 ORD SHS (NASDAQ), CAPRICOR THERAPEUTICS INC (NASDAQ), AIKIDO PHARMA INC (NASDAQ), LUMOS PHARMA INC (NASDAQ), NEUREN PHARMACEUTICALS LTD (ASX), PALATIN TECHNOLOGIES INC (NYSE American), LONGEVERON INC (NASDAQ), ANIXA BIOSCIENCES INC (NASDAQ), MATINAS BIOPHARMA HOLDINGS INC (NYSE American), ARMATA PHARMACEUTICALS INC (NYSE American), RECRO PHARMA INC (NASDAQ), DIFFUSION PHARMACEUTICALS INC (NASDAQ), SELLAS LIFE SCIENCES GROUP INC (NASDAQ), SAVARA INC (NASDAQ), CELYAD ONCOLOGY SPON ADS EACH REPR 1 ORD SHS (NASDAQ), CIDARA THERAPEUTICS INC (NASDAQ), AVALON GLOBOCARE CORP (NASDAQ), ENTASIS THERAPEUTICS HLDGS INC (NASDAQ), NEUROBO PHARMACEUTICALS INC (NASDAQ), KAZIA THERAPEUTICS LIMITED SPON ADR EACH REP 10 ORD SHS (NASDAQ), STEALTH BIOTHERAPEUTICS CORP SPON ADS EACH REP 12 ORD SHS (NASDAQ), VASCULAR BIOGENICS LTD (NASDAQ), ADVAXIS INC (NASDAQ), CELLECTAR BIOSCIENCES INC (NASDAQ), MERRIMACK PHARMACEUTICALS INC (NASDAQ), COHBAR INC (NASDAQ), PULMATRIX INCORPORATED (NASDAQ), AIM IMMUNOTECH INC (NYSE American), SYNTHETIC BIOLOGICS INC (NYSE American), WINDTREE THERAPEUTICS INC (NASDAQ), VACCINEX INC (NASDAQ), LEAF RESOURCES LTD (ASX), GENETIC TECHNOLOGIES (ASX), MONOPAR THERAPEUTICS INC (NASDAQ), CLEVELAND BIOLABS INC (NASDAQ), CHIMERIC THERAPEUTICS LTD (ASX), ORGANOVO HLDGS INC (NASDAQ), AZURRX BIOPHARMA INC (NASDAQ), SUNESIS PHARMACEUTICALS INC (NASDAQ), ENDRA LIFE SCIENCES INC (NASDAQ), CYNATA THERAPEUTICS LTD (ASX), VIRIDIAN THERAPEUTICS INC (NASDAQ), APPLIED DNA SCIENCES INC (NASDAQ), BIOCARDIA INC (NASDAQ), GENETIC TECHNOLOGIES SPON ADS EA REP 600 ORD SHS(R/S) (NASDAQ), ALTERITY THERAPEUTICS LIMITED (ASX), MICROBOT MEDICAL INC (NASDAQ), CATABASIS PHARMACEUTICALS INC (NASDAQ), MEMPHASYS LTD (ASX), ACORDA THERAPEUTICS INC (NASDAQ), ALTERITY THERAPEUTICS LIMITED SPON ADS EA REPR 60 ORD SHS (NASDAQ), ORAGENICS INC (NYSE American), ANPAC BIO MEDICAL SCIENCE CO LTD SPON ADS EACH REPR 1 ORD SHS CLASS A (NASDAQ), INDIA GLOBALIZATION CAPITAL INC (NYSE American), PRESCIENT THERAPEUTICS LIMITED (ASX), OPIANT PHARMACEUTICALS INC (NASDAQ), SOLIGENIX INC (NASDAQ), KIROMIC BIOPHARMA INC (NASDAQ), NABRIVA THERAPEUTICS PLC (NASDAQ), INVEX THERAPEUTICS LTD NPV (ASX), BIO-PATH HOLDINGS INC (NASDAQ), FORWARD PHARMA AS SPON ADS EACH REP 14 ORD SHS (NASDAQ), ALIMERA SCIENCES INC (NASDAQ), ATYR PHARMA INC (NASDAQ), PRECIPIO INC (NASDAQ), SONNET BIOTHERAPEUTICS HLDGS INC (NASDAQ), ADITX THERAPEUTICS INC (NASDAQ), ACHIEVE LIFE SCIENCE INC (NASDAQ), ARCA BIOPHARMA INC (NASDAQ), LIXTE BIOTECHNOLOGY HOLDINGS INC (NASDAQ), PHIO PHARMACEUTICALS CORP (NASDAQ), PATRYS LIMITED (ASX), BIOTRON (ASX), CYCLACEL PHARMACEUTICALS INC (NASDAQ), AURIS MEDICAL HOLDING LTD (NASDAQ), CYCLO THERAPEUTICS INC (NASDAQ), CAN FITE BIOPHARMA LTD SPON ADS EA REP 30 ORD SHS(POST REV SPL (NYSE American), AUSTRALIAN PRIMARY HEMP LTD (ASX), AVECHO BIOTECHNOLOGY LTD (ASX), ADALTA LTD (ASX), Suntar Eco-City (SGX), CONSTELLATION TECHNOLOGIES LTD (ASX), INMED PHARMACEUTICALS INC (NASDAQ), HISTOGEN INC (NASDAQ), CONTANGO ASSET MANAGEMENT LIMITED (ASX), HTG MOLECULAR DIAGNOSTICS INC (NASDAQ), MIDATECH PHARMA PLC SPON ADS EACH REP 5 ORD SHS(R/S) (NASDAQ), GEOVAX LABS INC (NASDAQ), ANCHIANO THERAPEUTICS LTD SPON ADS EACH REP 5 ORD SHS (NASDAQ), REGENEUS LTD (ASX), INVIVO THERAPEUTICS HOLDING CORP (NASDAQ), SENECA BIOPHARMA INC (NASDAQ), XENETIC BIOSCIENCES INC (NASDAQ), RHINOMED LIMITED (ASX), AMPLIA THERAPEUTICS LTD (ASX), BELLICUM PHARMACEUTICALS (NASDAQ), ACTINOGEN MEDICAL LTD (ASX), NOVABAY PHARMACEUTICALS INC (NYSE American), SENESTECH INC (NASDAQ), BENITEC BIOPHARMA INC (NASDAQ), NEUROSCIENTIFIC BIOPHARMA LTD (ASX), XTL BIOPHARMACEUTICALS LTD SPON ADS EACH REP 100 ORD SHS(POST SPLT) (NASDAQ), HOLISTA COLLTECH LIMITED (ASX), PLUS THERAPEUTICS INC (NASDAQ), CELLECT BIOTECHNOLOGY LTD SPON ADS EACH REP 100 ORD SHS(POST SPLT) (NASDAQ), ANATARA LIFESCIENCES LTD (ASX), NANOLLOSE LTD (ASX), CRYOSITE (ASX), LIVING CELL TECHNOLOGIES (ASX), FACTOR THERAPEUTICS LIMITED (ASX)
Notes:
  1. For companies, Market Cap is based on the trading currency of the company. Industry/Index Market Cap is the average market cap for that industry/index.
  2. Industry/Index PE is calculated using (Total Market Cap/Total Earnings) of all companies in the industry/index.
  3. Industry/Index Price/NAV is calculated using (Total Market Cap/Total Shareholders' Equity) of all companies in the industry/index.
  4. Industry/Index Dividend Yield is calculated using (Total Gross Dividend/Total Market Cap) of all companies in the industry/index.
  5. For Industry/Index calculation, data for foreign currency denominated companies will be converted to the main market currency using the latest exchange rate.
  6. Industry/Index/Peers data is updated daily.
  7. Peers are sorted by market capitalisation and only details for the top 10 will be shown.

Total Shareholder Return

PeriodDividend ReceivedCapital AppreciationTotal Shareholder Return
Short Term Return 5 Days --0.680
-4.86 %
10 Days --1.160
-8.01 %
20 Days --1.140
-7.88 %
Medium Term Return 3 Months --1.420
-9.63 %
6 Months --2.560
-16.12 %
1 Year --6.180
-31.69 %
Annualised Return Annualised --
-31.69 %
Notes:
  1. Total Shareholder Return (TSR) combines share price appreciation and dividends paid to show the total return to the shareholder expressed as a percentage.
  2. Script dividends are ignored in this calculation.

Price Movements

1 Year Range 12.140 - 24.150 Change From 1 Year Low +1.180 % Change From 1 Year Low (%) +9.72
Change From 1 Year High -10.830 % Change From 1 Year High (%) -44.84
2 Years Range 12.140 - 24.150 Change From 2 Years Low +1.180 % Change From 2 Years Low (%) +9.72
Change From 2 Years High -10.830 % Change From 2 Years High (%) -44.84
5 Years Range 12.140 - 24.150 Change From 5 Years Low +1.180 % Change From 5 Years Low (%) +9.72
Change From 5 Years High -10.830 % Change From 5 Years High (%) -44.84
Notes:
  1. Price movements are based on adjusted historical data.

Company Background

Alphamab Oncology is an investment holding company. It engages in the research and development, manufacturing and commercialization of biologics of oncology through its subsidiaries. The company was founded by Xu Ting in Novemeber 2008 and is headquartered in Suzhou, China.

Historical Price Data

Date Open High Low Close Volume VWAP
24 Feb 2021 13.280 13.540 12.140 12.300 3,272,000 12.6565
23 Feb 2021 13.600 13.800 13.260 13.260 2,947,000 13.4270
22 Feb 2021 13.720 13.880 13.540 13.620 2,826,000 13.6499
19 Feb 2021 13.880 14.080 13.540 13.720 2,191,000 13.6768
18 Feb 2021 13.900 14.320 13.820 13.900 2,448,000 13.9718
17 Feb 2021 14.000 14.280 13.880 14.000 1,128,000 14.0062
16 Feb 2021 14.360 14.800 14.020 14.100 1,208,000 14.2156
11 Feb 2021 14.360 14.360 14.220 14.360 203,000 14.2821
10 Feb 2021 14.000 14.580 14.000 14.480 1,065,000 14.2451
09 Feb 2021 14.000 14.140 13.860 14.000 512,000 13.9883
08 Feb 2021 14.000 14.460 13.880 13.980 1,906,000 14.1785
05 Feb 2021 13.740 14.060 13.620 13.720 751,000 13.8483
04 Feb 2021 14.600 14.800 13.700 13.960 1,914,000 14.0218
03 Feb 2021 14.280 15.000 14.020 14.440 4,379,000 14.6302
02 Feb 2021 13.940 14.280 13.560 13.940 2,807,000 13.9556
01 Feb 2021 13.340 13.960 13.340 13.880 2,057,000 13.7215
29 Jan 2021 14.200 14.200 13.200 13.300 1,647,000 13.4757
28 Jan 2021 14.400 14.400 13.580 13.580 4,046,324 13.9218
27 Jan 2021 14.920 14.920 14.180 14.460 2,131,000 14.3775
26 Jan 2021 15.560 15.600 14.000 14.800 5,864,000 14.6468
25 Jan 2021 15.620 16.200 15.460 15.560 3,347,810 15.7952
22 Jan 2021 15.140 15.940 15.020 15.540 5,738,000 15.4944
Summary
Current 2 Weeks
(09 Feb 2021 to 24 Feb 2021)		 14.000 14.800 12.140 12.300 17,800,000 -
Previous 2 Weeks
(26 Jan 2021 to 08 Feb 2021)		 15.560 15.600 12.140 13.980 27,502,324 -
4 Weeks from
(28 Dec 2020 to 25 Jan 2021)		 17.000 17.760 12.140 15.560 49,434,420 -
View All Historical Data

More Information Available

More information is available to our subscribers, including:

  • Market Moving News from Dow Jones Newswires
  • Consensus Estimates
  • Dividend/Distribution History
  • Financial Summary with Financial Period Comparison
  • Comprehensive Financial Ratios(ROA, ROE, Price/Revenue, Net Earnings Margin, Current Ratio, Debt to Equity Ratio etc)
  • Events Calendar for Results Announcements, Ex-Dates etc
  • Insider Buying and Selling Report

If you are an existing subscriber, please login. If not, read up on what you are missing out in our Help Centre and join us as a subscriber.

Disclaimer:

While reasonable efforts have been taken to ensure that the calculations performed by the features of this site are reliable, the features are provided on the basis that:-

  1. no liability is accepted for any errors or inaccuracies resulting from your use of these features;
  2. many of the data inputs (including share prices) are obtained from third party sources for which we assume no responsibility.
We use Cookies. By continuing to use this webite, you will be agreeing to our Privacy Policy, Terms and Conditions and Cookie Policy.